2410 — TYK Medicines Income Statement
0.000.00%
Last trade - 00:00- HK$4.23bn
- HK$3.99bn
Annual income statement for TYK Medicines, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 44.2 | 0 | 0.107 | 0 |
| Cost of Revenue | ||||
| Gross Profit | 20 | 0 | 0.014 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 341 | 361 | 375 | 291 |
| Operating Profit | -296 | -361 | -375 | -291 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -312 | -383 | -388 | -306 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -312 | -383 | -388 | -306 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | -311 | -382 | -387 | -300 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -311 | -382 | -387 | -300 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.839 | -1.01 | -0.97 | -0.821 |